Pilot study on use of Sulphur hexafluoride Microbubbles (SonoVue®) as a Magnetic Resonance Imaging contrast agent in the imaging of brain tumours. - Mr Bubbles

Alder Hey Children's NHS Foundation Trust0 个研究点开始时间: 2013年9月3日最近更新: 2013年10月14日

适应症

试验速览

暂无简介。

•1.Patients undergoing pre-operative MRI investigation for a known enhancing intracranial neoplasm.
•2.Patients undergoing follow up MRI investigation for an intracranial neoplasm (including residual neoplasm)
•3.Patient/ guardian provides written informed consent and is willing to comply with the protocol requirements
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 0

•1.Patients with non-enhancing tumours
•2.Contraindications to SonoVue ® (Appendix 1 in the protocol)and/or Gadolinium
•Allergy to sulphur hexafluoride or sulphur containing medication
•Known cardiac disorders
•Adult respiratory distress syndrome
•Pregnant and lactating females – All females of child bearing age will have a pregnancy test.
•3.Patients with acute or chronic renal disease (risk of gadolinium induced toxicity)
•4.Patients with allergic /atopic tendency: History of asthma or allergic reaction to food or drugs leading to urticarial, bronchospasm, hypotension or anaphylactoid reaction.
•5.Patients with contraindication to undergo MR imaging (Cochlear implant, pacemaker, claustrophobia etc).

发起方